カテゴリ： GlobalData, アメリカ, 企業調査

Arena Pharmaceuticals Inc (ARNA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Arena Pharmaceuticals Inc (ARNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10075
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. It is evaluating its lead candidate etrasimod for multiple inflammatory indications including ulcerative colitis, primary biliary cholangitis, pyoderma gangrenosum, and dermatologic extraintestinal manifestations of irritable bowel syndrome. The company is investigating ralinepag for the treatment of pulmonary arterial hypertension (PAH); and APD371 for pain associated with Crohn’s disease. Arena is also developing Belviq (lorcaserin HCl) for chronic weight management for adults with obesity; nelotanserin for patients with Lewy body dementia (LBD) suffering from visual hallucinations. It has collaborations with Eisai, Axovant Sciences, Boehringer Ingelheim, and Beacon Discovery Inc. It has a manufacturing facility in Zofingen, Switzerland. Arena is headquartered in San Diego, California, the US.

Arena Pharmaceuticals Inc (ARNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Arena Pharma and Everest Medicines Enter into Agreement 12
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14
Abic Marketing Enters into Agreement with Arena Pharma 15
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20
Licensing Agreements 21
Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24
Equity Offering 25
Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29
Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31
Arena Pharma to Raise Funds through Public Offering of Shares 32
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 33
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 34
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 36
Asset Transactions 38
Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38
Arena Pharmaceuticals Inc – Key Competitors 39
Arena Pharmaceuticals Inc – Key Employees 40
Arena Pharmaceuticals Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 06, 2018: Arena Pharmaceuticals provides corporate update and reports second quarter 2018 financial results 42
May 08, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results 44
Mar 14, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 45
Nov 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results 47
Aug 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results 48
May 09, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results 50
Mar 14, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 51
Corporate Communications 53
Jul 10, 2018: Arena Pharmaceuticals Names Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors 53
Feb 16, 2018: Arena Pharmaceuticals Announces Board Changes 54
Jun 14, 2017: Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors 55
Mar 20, 2017: Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer 56
Feb 14, 2017: Arena Pharmaceuticals Appoints Three New Members to Board of Directors 57
Product News 58
02/09/2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn’s and Colitis Organisation – Inflammatory Bowel Diseases 2017 58
01/22/2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City 59
Clinical Trials 61
Oct 08, 2018: Arena Pharmaceuticals presented phase 2 clinical data for Etrasimod in ulcerative colitis at the American College of Gastroenterology Annual Meeting 61
Oct 02, 2018: Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension 62
Sep 24, 2018: Arena Pharmaceuticals reports positive phase 2a results for Olorinab in patients with abdominal pain associated with Crohn’s disease 63
Sep 17, 2018: Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress 64
Aug 28, 2018: Arena Pharmaceuticals presented phase 1 clinical data for Ralinepag in pulmonary arterial hypertension at the European Society of Cardiology 65
May 21, 2018: Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference 66
Apr 12, 2018: Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting 67
Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis 68
Mar 01, 2018: Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn’s Disease at American Pain Society Annual Scientific Summit 69
Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis 70
Oct 19, 2017: Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting 71
Sep 06, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society 72
Aug 22, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress 73
Jul 10, 2017: Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension 74
Jun 29, 2017: Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers 75
May 18, 2017: Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City 76
May 16, 2017: Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference 77
Apr 17, 2017: Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arena Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arena Pharma and Everest Medicines Enter into Agreement 12
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14
Abic Marketing Enters into Agreement with Arena Pharma 15
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20
Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24
Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29
Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31
Arena Pharma to Raise Funds through Public Offering of Shares 32
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 33
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 34
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 36
Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38
Arena Pharmaceuticals Inc, Key Competitors 39
Arena Pharmaceuticals Inc, Key Employees 40
Arena Pharmaceuticals Inc, Other Locations 41
Arena Pharmaceuticals Inc, Subsidiaries 41

List of Figures
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Arena Pharmaceuticals Inc (ARNA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Chubb European Group SE：企業の戦略的SWOT分析
    Chubb European Group SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Dartmouth College：製薬・医療：M&Aディール及び事業提携情報
    Summary Dartmouth College (Dartmouth) is an educational institution that offers education and research services. The institute provides various programs in the field of art history, languages and literatures, english and creative writing, film and media studies, sociology, psychological and brain sc …
  • PKO Bank Polski SA：企業の戦略・SWOT・財務情報
    PKO Bank Polski SA - Strategy, SWOT and Corporate Finance Report Summary PKO Bank Polski SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Ominto Inc：企業の戦略的SWOT分析
    Ominto Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Sumitomo Mitsui Trust Holdings Inc：企業の戦略・SWOT・財務情報
    Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Energen Corporation：企業の戦略・SWOT・財務情報
    Energen Corporation - Strategy, SWOT and Corporate Finance Report Summary Energen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Territorial Generating Company #2 (TGKB)：企業の財務・戦略的SWOT分析
    Territorial Generating Company #2 (TGKB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Nintendo Co Ltd (7974)：企業の財務・戦略的SWOT分析
    Nintendo Co Ltd (7974) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • BDO International Limited：企業の戦略・SWOT・財務分析
    BDO International Limited - Strategy, SWOT and Corporate Finance Report Summary BDO International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • PositiveID Corp (PSID)：企業の財務・戦略的SWOT分析
    Summary PositiveID Corp (PositiveID) formerly VeriChip Corp is a life sciences tools and diagnostics company that develops biological detection and molecular diagnostic systems. The company develops microfluidic systems for automated preparation and performance of biological assays. Its products inc …
  • Exelon Generation Company LLC：発電所・企業SWOT分析
    Exelon Generation Company LLC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • High-Tech Grunderfonds Management GmbH：企業のM&A・事業提携・投資動向
    High-Tech Grunderfonds Management GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's High-Tech Grunderfonds Management GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Republic National Distributing Co：企業の戦略・SWOT・財務情報
    Republic National Distributing Co - Strategy, SWOT and Corporate Finance Report Summary Republic National Distributing Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • New England Biolabs Inc-医療機器分野：企業M&A・提携分析
    Summary New England Biolabs Inc (NEB) is a life science company that develops recombinant and native enzymes for genomic research. The company offers products such as competent cells, DNA plasmids, protein tools, buffers and strains, and others. It has applications in cloning and synthetic biology, …
  • DocCheck AG (AJ91)：企業の財務・戦略的SWOT分析
    DocCheck AG (AJ91) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • GenePOC Inc：医療機器：M&Aディール及び事業提携情報
    Summary GenePOC Inc (GenePOC), a subsidiary of Debiopharm Group, is a medical device company that develops rapid molecular devices for providing targeted therapy. The company offers on-the-spot diagnostic devices for achieving optimal patient management. It offers diagnostic instruments based on a n …
  • Robert Half International Inc.：企業の戦略・SWOT・財務情報
    Robert Half International Inc. - Strategy, SWOT and Corporate Finance Report Summary Robert Half International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • HTL International Holdings Limited：企業の戦略的SWOT分析
    HTL International Holdings Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Powszechny Zaklad Ubezpieczen Group：戦略・SWOT・企業財務分析
    Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report Summary Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • AcelRx Pharmaceuticals Inc (ACRX)：企業の財務・戦略的SWOT分析
    AcelRx Pharmaceuticals Inc (ACRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆